Azitra (AZTR) Stock Price

Azitra Price

ASX·CLOSED
0.07
​
Market closed

Revenue at Azitra has contracted by 59.1% per year over the past 3 years to 7,500.00 USD. Azitra's net margin stands at -119,566.6%, down from -8,127.0% several years earlier.

Azitra stock price

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Azitra business model & stock analysis

Azitra Inc., based in Branford, Connecticut, is an early-stage biopharmaceutical company focused on developing topical therapies for dermatological conditions. The company utilizes engineered proteins and live biotherapeutic products, leveraging a microbial library of 1,500 bacterial strains and AI-driven screening to create treatments for skin diseases. Its pipeline includes ATR-12 for Netherton syndrome, ATR-04 for papulopustular rash, and ATR-01 for ichthyosis vulgaris, all targeting unmet medical needs in precision dermatology. Listed on June 16, 2023, Azitra operates with a team of 10 employees.

Frequently asked questions about Azitra

7 analysts currently rate the Azitra stock: 6 recommend buying, 1 holding and 0 selling.

Converted at the current exchange rate, the Azitra share trades at 0.06 EUR (0.07 USD).

The Azitra share (AZTR) is listed on 1 stock exchanges, including: ASX (AZTR).

The revenue cannot currently be calculated for Azitra.

The expected profit of Azitra is -2.15 M USD. The net profit reflects the company's profitability after deducting all expenses.

The price-to-earnings ratio (P/E) of Azitra is currently -0.36. The P/E ratio compares the current share price to the earnings per share and helps investors assess the valuation of the Azitra stock.

The P/S cannot be calculated for Azitra currently.

The Eulerpool Quality Score for Azitra is 2/10.

The ISIN of Azitra is US05479L3024. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.

The ticker of Azitra is AZTR. The ticker symbol is used to trade Azitra shares on the stock exchange.

Fair ValueTerminal
0.06 USD
Over-/UndervaluationTerminal
Fairly valued
Sector
Industry
Biotechnology
Number of shares
Employees
Revenue growth Ø5 years
EBIT growth Ø5 years
Net Income growth Ø5 years
Currency
USD
Initial public offering
Jun 16, 2023
ISIN
US05479L3024
Cusip
05479L104
Market capitalization
52-Week Range
PEG
—
P/E ratio
P/Ee 2026
-0.36
P/Ee 2027
-0.76
P/Ee 2028
-0.90
P/Ee 2029
-1.20
P/Ee 2030
0.42
P/Se
—
EV/EBIT
0.08
P/B Ratio
0.20
ROE (Return on Equity)
ROA (Return on Assets)
ROCE (Return on Capital Employed)
ROIC (Return on Invested Capital)
-259.40 %
Last updated Oct 21, 2026, 4:23 PM

Azitra Peer Group

Azitra Ticker

AUSTRALIEN SECURITIES · AZTR

All fundamentals and in-depth analysis of Azitra

Our stock analysis for Azitra stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Azitra. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.